Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1950 1
1952 2
1953 1
1954 1
1956 2
1958 1
1974 2
1975 1
1979 2
1980 6
1981 7
1982 1
1983 1
1985 1
1986 1
1987 2
1988 5
1989 3
1990 8
1991 5
1992 12
1993 9
1994 11
1995 16
1996 13
1997 9
1998 19
1999 22
2000 15
2001 35
2002 20
2003 23
2004 17
2005 23
2006 24
2007 30
2008 38
2009 30
2010 49
2011 59
2012 40
2013 60
2014 59
2015 52
2016 58
2017 46
2018 46
2019 47
2020 66
2021 66
2022 64
2023 66
2024 67
2025 41

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,187 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators. Motzer RJ, et al. Among authors: grimm mo. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21. N Engl J Med. 2018. PMID: 29562145 Free PMC article. Clinical Trial.
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial.
Tannir NM, Albigès L, McDermott DF, Burotto M, Choueiri TK, Hammers HJ, Barthélémy P, Plimack ER, Porta C, George S, Donskov F, Atkins MB, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Tomita Y, Castellano D, Grünwald V, Rini BI, Jiang R, Desilva H, Fedorov V, Lee CW, Motzer RJ. Tannir NM, et al. Among authors: grimm mo. Ann Oncol. 2024 Nov;35(11):1026-1038. doi: 10.1016/j.annonc.2024.07.727. Epub 2024 Aug 2. Ann Oncol. 2024. PMID: 39098455 Free PMC article. Clinical Trial.
Toll-Like Receptor 3 Mediates Aortic Stenosis Through a Conserved Mechanism of Calcification.
Gollmann-Tepeköylü C, Graber M, Hirsch J, Mair S, Naschberger A, Pölzl L, Nägele F, Kirchmair E, Degenhart G, Demetz E, Hilbe R, Chen HY, Engert JC, Böhm A, Franz N, Lobenwein D, Lener D, Fuchs C, Weihs A, Töchterle S, Vogel GF, Schweiger V, Eder J, Pietschmann P, Seifert M, Kronenberg F, Coassin S, Blumer M, Hackl H, Meyer D, Feuchtner G, Kirchmair R, Troppmair J, Krane M, Weiss G, Tsimikas S, Thanassoulis G, Grimm M, Rupp B, Huber LA, Zhang SY, Casanova JL, Tancevski I, Holfeld J. Gollmann-Tepeköylü C, et al. Among authors: grimm m. Circulation. 2023 May 16;147(20):1518-1533. doi: 10.1161/CIRCULATIONAHA.122.063481. Epub 2023 Apr 4. Circulation. 2023. PMID: 37013819 Free PMC article.
[Immunotherapy].
Grimm MO, Loidl W. Grimm MO, et al. Urologe A. 2018 Nov;57(11):1299-1300. doi: 10.1007/s00120-018-0796-y. Urologe A. 2018. PMID: 30406452 German. No abstract available.
[Renal cell carcinoma].
Grimm MO, Doehn C, Krege S. Grimm MO, et al. Urologe A. 2020 Feb;59(2):133-134. doi: 10.1007/s00120-020-01130-y. Urologe A. 2020. PMID: 32076795 German. No abstract available.
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JÁ, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD. Sharma P, et al. Among authors: grimm mo. Lancet Oncol. 2017 Mar;18(3):312-322. doi: 10.1016/S1470-2045(17)30065-7. Epub 2017 Jan 26. Lancet Oncol. 2017. PMID: 28131785 Clinical Trial.
Comprehensive genomic characterization of early-stage bladder cancer.
Prip F, Lamy P, Lindskrog SV, Strandgaard T, Nordentoft I, Birkenkamp-Demtröder K, Birkbak NJ, Kristjánsdóttir N, Kjær A, Andreasen TG, Ahrenfeldt J, Pedersen JS, Rasmussen AM, Hermann GG, Mogensen K, Petersen AC, Hartmann A, Grimm MO, Horstmann M, Nawroth R, Segersten U, Sikic D, van Kessel KEM, Zwarthoff EC, Maurer T, Simic T, Malmström PU, Malats N, Jensen JB; UROMOL Consortium; Real FX, Dyrskjøt L. Prip F, et al. Among authors: grimm mo. Nat Genet. 2025 Jan;57(1):115-125. doi: 10.1038/s41588-024-02030-z. Epub 2025 Jan 3. Nat Genet. 2025. PMID: 39753772 Free PMC article.
[Travel medicine].
Schubert S, Grimm M. Schubert S, et al. Among authors: grimm m. Internist (Berl). 2009 Jul;50(7):841-51. doi: 10.1007/s00108-009-2433-8. Internist (Berl). 2009. PMID: 19484193 Review. German.
1,187 results